Giordano Novak Rossi (Giordano Rossi, Giordano N Rossi)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 11

Top Topics

Randomized Controlled Trial

Major Depressive Disorder

Top Venues

Expert opinion on drug safety

Human psychopharmacology

Risk management and healthcare policy

This page only lists publications with an associated author ORCID identifier.

Publications

Genís Ona, Ingrid Reverte, Giordano Novak Rossi, Rafael Guimarães Dos Santos, Jaime Ec Hallak, Maria Teresa Colomina, José Carlos Bouso Saiz
Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: A mechanistic overview. Journal of psychopharmacology (Oxford, England) (2023)
Felipe Fernandes Vieira de Lima, Giordano Novak Rossi, Rafael Guimarães Dos Santos, Flávia de Lima Osório
Multifaceted Empathy Test (MET): Validity evidence for the Brazilian population concerning the computer-based (face-to-face) and online versions. PloS one 18 (7) (2023)
José Diogo R Souza, Julia Cozar Pacheco, Giordano Novak Rossi, Bruno O de-Paulo, Antonio W Zuardi, Francisco S Guimarães, Jaime E C Hallak, José Alexandre de Souza Crippa, Rafael Guimarães Dos Santos
Adverse Effects of Oral Cannabidiol: An Updated Systematic Review of Randomized Controlled Trials (2020-2022). Pharmaceutics 14 (12) (2022)
José Diogo R Souza, Julia Cozar Pacheco, Giordano Novak Rossi, Bruno O de-Paulo, Antonio W Zuardi, Francisco S Guimarães, Jaime E C Hallak, José Alexandre de Souza Crippa, Rafael Guimarães Dos Santos
Adverse Effects of Oral Cannabidiol: An Updated Systematic Review of Randomized Controlled Trials (2020-2022). Pharmaceutics 14 (12) (2022)
José Diogo R Souza, Julia Cozar Pacheco, Giordano Novak Rossi, Bruno O de-Paulo, Antonio W Zuardi, Francisco S Guimarães, Jaime E C Hallak, José Alexandre de Souza Crippa, Rafael Guimarães Dos Santos
Adverse Effects of Oral Cannabidiol: An Updated Systematic Review of Randomized Controlled Trials (2020-2022). Pharmaceutics 14 (12) (2022)
Giordano Novak Rossi, Isabella Caroline da Silva Dias, Glen Baker, José Carlos Bouso Saiz, Serdar M Dursun, Jaime E C Hallak, Rafael Guimarães Dos Santos
Ayahuasca, a potentially rapid acting antidepressant: focus on safety and tolerability. Expert opinion on drug safety 21 (6) (2022)
Rafael Guimarães Dos Santos, Juliana Mendes Rocha, Giordano Novak Rossi, Flávia L Osório, Genís Ona, José Carlos Bouso Saiz, Gabriela de Oliveira Silveira, Mauricio Yonamine, Camila Marchioni, Eduardo José Crevelin, Maria Eugênia Queiroz, José Alexandre Crippa, Jaime E C Hallak
Effects of ayahuasca on the endocannabinoid system of healthy volunteers and in volunteers with social anxiety disorder: Results from two pilot, proof-of-concept, randomized, placebo-controlled trials. Human psychopharmacology 37 (4) (2022)
Giordano Novak Rossi, Lorena T L Guerra, Glen B Baker, Serdar M Dursun, José Carlos Bouso Saiz, Jaime E C Hallak, Rafael Guimarães Dos Santos
Molecular Pathways of the Therapeutic Effects of Ayahuasca, a Botanical Psychedelic and Potential Rapid-Acting Antidepressant. Biomolecules 12 (11) (2022)
Giordano Novak Rossi, Jaime E C Hallak, José Carlos Bouso Saiz, Rafael Guimarães Dos Santos
Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges. Expert opinion on drug safety 21 (6) (2022)
Rafael Guimarães Dos Santos, José Carlos Bouso, Juliana Mendes Rocha, Giordano Novak Rossi, Jaime E Hallak
The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges. Risk management and healthcare policy 14 (2021)
Gabriela de Oliveira Silveira, Rafael Guimarães Dos Santos, Felipe Rebello Lourenço, Giordano Novak Rossi, Jaime E C Hallak, Mauricio Yonamine
Stability Evaluation of DMT and Harmala Alkaloids in Ayahuasca Tea Samples. Molecules (Basel, Switzerland) 25 (9) (2020)